SciHub
文献互助
期刊查询
一搜即达
科研导航
即时热点
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!
七七
Lv5
1120 积分
2021-09-15 加入
最近求助
最近应助
互助留言
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
4天前
已完结
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
6天前
已完结
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
6天前
已完结
Pharmacokinetics
1个月前
已关闭
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
4个月前
已完结
Method validation of a bridging immunoassay in combination with acid-dissociation and bead treatment for detection of anti-drug antibody
4个月前
已完结
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
5个月前
已完结
CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer
9个月前
已完结
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
10个月前
已完结
Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma
11个月前
已关闭
没有进行任何应助
速度真快
4天前
帮大忙了
6天前
速度真快
6天前
书籍下载比较困难,先不求助了【积分已退回】
1个月前
您好,我求助的是书籍,不是文章,虽然文章题目相同,但不是您上传这篇文章的作者,作者是错误的,辛苦您了,但不好意思,信息不对,需要驳回
1个月前
速度真快
4个月前
速度真快
5个月前
速度真快
9个月前
么么哒,帮大忙了,速度真快
10个月前
无人应答【积分已退回】
11个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论